Contact Us    Downloads    Login 
   

              
 

Case Studies


Cenix

  • Engaged with RNAi biotech company at invitation of principal shareholders
  • Developed IM and divestment strategy to realise exit for investors
  • Divested primary technology platform to Ambion, who were the principal distributor for the company, acquired in turn by ABI, thereby returning some capital to investors and providing company a base for continued operations a final sale efforts.
  • Developed second strategic alliance programme for company for joint R&D programme and ultimate equity acquisition options
  • Developed and implemented strategy for exit of investors from remaining company

 Return to all case studies




Oxford UK – 19th April 2010 – Sense Proteomic Ltd. has announced the appointment of The Sage Group as its business development consultant to assist in expanding its global biomarker discovery partnerships. Sense is part of Ox...Read entire article



Cambridge UK and Clinton USA – December 2009 – The Sage Group is pleased to announce the appointment of two new seasoned Executive Directors – Dr. Tom Geimer in Australia and Dr. Laurence Shaw in Israel. Drs. Geimer and...Read entire article



Cambridge UK and Clinton USA – December, 2009 – The Sage Group, Inc. is pleased to announce the expansion of its global network with the opening of an Israeli office and the appointment of Dr. Laurence Shaw as Executive Direc...Read entire article

Contact Us

If you are interested in contacting us or obtaining the contact details for one of our offices, please use our contact page.

If you would like to make a more comprehensive business enquiry, you can send us further details of your company using our Business Enquiry Form.

© The Sage Group 2008 Site by YouSoft   Privacy Policy   Contact us